Oddity Tech is ready to unveil its third brand.
The parent company of Il Makiage and SpoiledChild is debuting Methodiq, a telehealth platform with an initial focus on acne, hyperpigmentation and eczema.
“The launch of Methodiq allows Oddity to better serve the growing base of over 60 million users on our platform. A large portion suffer from conditions like acne, eczema and hyperpigmentation — and many are dissatisfied with the solutions available to them,” said Oran Holtzman, cofounder and chief executive officer of Oddity. “Building on our success in beauty, we are now unleashing our technology and direct-to-consumer model to transform a large, underserved medical care market with significant long-term growth potential for us.”
Methodiq’s approach to dermatology comes via integrating AI-powered skin analysis, computer vision-based progress tracking, and prescription and non-prescription treatments.
Through the Methodiq App, users then complete weekly check-ins where the vision models track improvement and share insights directly with the assigned clinician, enabling real-time adjustments.
The platform does not take insurance.
Methodiq launches with 28 core products and more than 100 personalized treatment plans. The products span prescription, OTC, and cosmetic formulations — including a selection of products powered by proprietary, AI-discovered ingredients from Oddity Labs, the company’s biotech based in Boston.
Acne treatments include Clindalaq 305, an acne topical prescription featuring clindamycin, tretinoin and niacinamide; Trazelaq 305 for persistent acne; Spironolactone, a prescription oral treatment, and Zeralaq, an acne scar treatment powered by ODDL103.
It’s also tackling acne with makeup products via SkinShield, a dermatologist-developed foundation for acne-prone skin, and SpotShield, a concealer formulated with salicylic acid, niacinamide, panthenol and bacillus ferment.
“From Day One, we worked hand-in-hand with doctors to design next-generation healthcare built around the patient,” added Tom Amsterdam, CEO of Methodiq. “We reimagined every layer, product, and protocol — to deliver smarter, more effective care with less friction. Methodiq isn’t about improving what exists; it’s about rebuilding it the right way.”
Its marketing campaign will encompass billboards and a campaign on the New York City subway.
Oddity’s net revenue rose to $241 million in the second quarter ended June 30, from $193 million in the same period of 2024. Analysts had penciled in $238 million.
For the full year ending Dec. 31, it is now forecasting net revenue between $799 million and $804 million, up from the previous outlook of $790 million to $798 million.
Adjusted diluted earnings per share are expected to come in between $2.06 and $2.09, compared with between the $1.99 and $2.04 previously forecast.
Brand four is set to be launched next year.
